Mastocytosis clinical trials

Explore recruiting mastocytosis clinical trials.

Recruiting mastocytosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Mastocytosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A 24-week with possible extension, prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, phase III study to compare efficacy and safety of oral masitinib to placebo in treatment of patients with Smouldering or Indolent Severe Systemic mastocytosis with handicap, unresponsive to optimal symptomatic treatment

Poland, France, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Hydroxychloroquine in isolated cutaneous mastocytosis patients or indolent systemic mastocytosis with associated skin involvement patients: proof of concept study (HCQMa)

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

The use of dupilumab in treatment of indolent systemic mastocytosis with skin involvement

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

(Summit) A Multi-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of the Safety and Efficacy of CGT9486 in Subjects with NonAdvanced Systemic Mastocytosis

Netherlands, Czechia, France, Spain, Norway, Poland +6 more

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-label, Multicenter, Rollover Study in Patients Who Participated in an Avapritinib Clinical Study

Italy, Netherlands, Belgium, Norway, Sweden

Therapeutic use (Phase IV) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis

Portugal, Denmark, Sweden, France, Spain, Germany +9 more

Phase II and Phase III (Integrated) EU CTIS Study details

Mastocytosis trials by city

Mastocytosis in Toronto Mastocytosis in Vancouver Mastocytosis in Montreal Mastocytosis in Calgary Mastocytosis in Edmonton Mastocytosis in Ottawa Mastocytosis in Winnipeg Mastocytosis in Quebec City Mastocytosis in Hamilton Mastocytosis in Kitchener Mastocytosis in London Mastocytosis in Halifax Mastocytosis in New York Mastocytosis in Los Angeles Mastocytosis in Chicago Mastocytosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease